NEW YORK (360Dx) – Roche said today that it has obtained CE marking for the Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with the Novartis drug Zykadia (ceritinib).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.